3 Innovative Ways Researchers Are Rethinking How We Combat the Flu
Did you like reading this story? Click the heart to show your love.
A Message from Chairman and CEO Alex Gorsky About the Emergency Use Authorization of Johnson & Johnson's Janssen COVID-19 VaccineDid you like reading this message? Click the heart to show your love.
Johnson & Johnson Chairman and CEO Appears at the White House to Discuss the Company's Collaboration with Merck and Future Vaccine ProductionDid you like reading this story? Click the heart to show your love.
f you think the flu is nothing more than just a bad cold, you're dangerously misinformed. While it's true that some people experience only mild symptoms, according to the Centers for Disease Control and Prevention (CDC), between 140,000 and 960,000 Americans are hospitalized each year with flu-related complications.
Globally, the flu kills up to 650,000 people annually, according to the World Health Organization (WHO). That translates to about one death every 60 seconds, says , Vice President, Disease Area Stronghold Leader for Respiratory Infections Research and Development, Janssen Pharmaceutical Companies of Johnson & Johnson.
While efforts to prevent the flu have come a long way since the first major pandemic hit in 1918, there's still far more that needs to be done to keep the virus in check.
"During the 2018 to 2019 season, vaccine efficacy was only around 20 to 30%,” Dr. Chien says. “Even during the 'best' seasons it's only about 50% effective [at preventing the flu]."
The main problem? The flu virus mutates, and several strains of it are often in circulation at once.
What if, instead of formulating a vaccine based on a guess about which strains are most apt to be circulating in a given year, scientists could create a single vaccine that would protect against all types of flu?ShareDid you like reading this story? Click the heart to show your love.
"Currently, scientists predict which strains will be most prevalent in the coming flu season and distribute vaccines that aim to prevent infection by these strains,” explains, Vice President, Global Head of Viral Vaccine Discovery and Translational Medicine and Disease Area Stronghold Leader for Viral Vaccines at Janssen. “However, strains may evolve in an unforeseen way, so that the vaccine doesn’t match the circulating strains."
Another issue is that while existing drugs can help shorten the severity of the virus, it's only by about a day—and only when taken within two days of the onset of symptoms. Some flu sufferers might not realize they even have the virus until after that window has closed.
Enter researchers who are focused on helping change all of this.
As we head into peak flu season, learn how they are exploring new and improved ways to both prevent and treat the onerous virus.
A potential alternative to the flu shot
If you dread rolling up your sleeve in anticipation of a needle jab, take heart: Just a few months ago, Janssen entered into a partnership with Vaxart, a biotech company that's working on developing an oral flu vaccine in the form of a pill.
More good news for needle-phobes: Janssen is also in the early stages of developing a universal nasal flu vaccine, which has the potential to be more effective than the nasal vaccine currently on the market.
"We're in the preclinical phase of investigating multiple preventative and treatment approaches right now, with the goal of covering more strains of flu—and bringing effective solutions to more people—with an oral approach," Dr. Chien says.
A potential new treatment option
While there are antiviral drugs that can attack the flu virus and stop it from multiplying, their power is limited: The current ones must be taken within two days after the first symptoms strike for optimal results, and they only shave about 24 hours off the illness's duration. So if you show up at the hospital several days into the flu with serious complications, there are no data to suggest these antivirals will be effective in treating the flu infection.
A new compound being developed by Janssen might be able to help make a difference. In 2014, Janssen entered into an exclusive license agreement with Vertex Pharmaceuticals to develop the compound, which has a different mechanism of action from existing antiviral drugs. Since then, a series of clinical trials has shown that the treatment, especially when used in conjunction with another commonly used antiviral, can help cut the viral load—that is, the amount of virus that's present—in patients who've contracted a strain called influenza A, which is the type most often associated with large flu epidemics.
Two Phase 3 studies of the compound are currently underway, with results of the trial, which is being supported by the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services, expected next year.
A potential vaccine that could work for every type of flu
What if, instead of formulating a vaccine based on a guess about which strains are most apt to be circulating in a given year, scientists could create a single vaccine that would protect against all types of flu?
That's exactly what researchers at Janssen—with support from BARDA—are attempting to do.
For instance, they've designed molecules, called mini-HA antigens, containing parts of the flu virus that occur across a wide variety of viruses. The thinking is that vaccinations containing these antigens might be able to provide protection against many more strains of the flu virus than current vaccines do.
The project is still in the early exploratory stages, but, says Schuitemaker, "a 'universal' flu vaccine may potentially take away the burden of almost yearly updates and may even make us better prepared for an influenza pandemic, which is recognized by the WHO as one of the top global health threats."
In the meantime, the best protection against the flu is still the good old-fashioned shot. So if you haven’t gone for your vaccine yet, consider it to protect yourself—and others around you—from the flu.